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Introduction
Deregulation of the cyclin D1-CDK4/6-retinoblastoma pathway is implicated in breast cancer biology and in endocrine treatment resistance [1] . However, unlike the majority of triple negative breast cancers, Rb is usually intact in Hormone Receptor positive (HRþ) breast cancer [1] , and there has been considerable therapeutic interest in CDK 4/6 inhibitors in HRþ breast cancer. Indeed, over the past 3 years, multiple large-scale clinical trials have demonstrated that inhibiting CDK 4/6 leads to significant clinical benefit when combined with standard endocrine therapies in metastatic HRþ breast cancer [2] [3] [4] [5] [6] [7] [8] .
Palbociclib is a first-in-class, highly selective, CDK 4/6-inhibitor that has proven efficacy against HRþ, human epidermal growth factor receptor 2 negative (HER2À) metastatic breast cancer (mBC). In February 2015, the FDA granted accelerated approval to CDK 4/6-inhibitor, palbociclib, in combination with letrozole for first-line treatment of post-menopausal women with HRþ/ HER2À metastatic breast cancer (mBC), and in February 2016 palbociclib also received approval by the FDA in combination with fulvestrant for the treatment of HRþ, HER2À, endocrine therapyresistant mBC. Similar studies have led to the approval of ribociclib and abemaciclib in 2017 [6, 7] . Currently CDK 4/6 inhibitors, including palbociclib, ribociclib and abemaciclib, are being increasingly employed in clinical practice. However, patients eventually have disease progression but major questions remain unanswered, including the clinical development of resistance to this class of drugs.
In this paper, we describe the acquisition of de novo RB1 mutations in three patients who were treated with CDK 4/6 inhibitors. We hypothesize that these acquired, mutational events may be implicated in the development of resistance to CDK 4/6 inhibitors.
Patients and methods
Identification of somatic genomic mutations by next-generation sequencing Patient 1. Tissue and peripheral blood samples were collected at the Institut Gustave Roussy according to local procedure. The tissue DNA was extracted from biopsy sample using the FFPE DNAeasy Kit (Qiagen, Hilden, Germany) and quantified with Qubit 2.0 (Life Technologies, Darmstadt, Germany). A total of 10 ml blood samples were collected in EDTA-tubes (BD Vacutainer -Beckton, Dickinson and Company, Franklin Lakes, NJ) and centrifuged for 10 min at 1000 g within 4 h from the blood draw, as previously described [6] . DNA was extracted from 3 ml of plasma using the QIamp circulating nucleic acid kit (Qiagen), according to the manufacturer's instructions. A real-time quantitative polymerase chain reaction (PCR) TaqMan TM assay targeting GAPDH was used to quantify plasma DNA concentration.
Targeted sequencing libraries were generated using the Ion AmpliSeq Library kit 2.0, according to the manufacturer's instructions (Life Technologies), as previously described [8] . The custom designed ampliseq primer pools (Life Technologies) used for library amplification convert 93% of the RB1 coding sequence and 95% of the TP53 coding sequence. Tumor and plasma samples were analyzed independently. The sequencing data were analyzed with the Torrent Suite Variant Caller software and annotated using the reference genome hg19 (GRCh37). All variants were visualized on bam-file using Alamut Visual version 2.9 (Interactive Biosoftware, Rouen, France). An average of 405Â and 589Â coverage depth was obtained for tissue sample and plasma sample, respectively.
Patient 2. Next-generation sequencing (NGS) on tumor tissue was carried out utilizing the institutional platform (SNaPshot). The SNaPshot assay utilizes a multiplex PCR technology called Anchored Multiplex PCR for single-nucleotide variant (SNV) and insertion/deletion (indel) detection in genomic DNA using NGS. A sequencing library targeting hotspots and exons in 39 genes was generated using two hemi-nested PCR reactions. This assay has been validated to detect SNV and indel variants at 5% allelic frequency or higher in target regions with sufficient read coverage [9] .
Circulating tumor DNA (ctDNA) analysis was carried out using the commercially available Guardant360 assay, an NGS-based assay that identifies potential tumor-related (somatic) genomic alterations via complete exon sequencing of the critical exons within 73 cancer-related genes, including select exons of RB1, with high clinical sensitivity rates (85% in stage III/IV solid tumors) and very high specificity (>99.9%) as described previously [10] . Briefly, following cfDNA isolation, 5-30 ng of DNA underwent oligonucleotide barcoding for digital sequencing library preparation. Each of the cancer-related genes was pair-end sequenced on an Illumina HiSeq 2500. Each base pair had a 15 000Â average coverage depth. After sequencing, algorithmic reconstruction of the digitized sequencing signals was used to reconstruct the cfDNA fragments as previously reported [10] .
Patient 3. NGS on tumor tissue was carried out utilizing the commercial
Foundation Medicine platform, covering 322 genes, median depth of >500Â and >99% specificity. ctDNA analysis was carried out using the commercially available Guardant360 assay, similar to patient 2 [10] .
The technical details of all the assays are summarized in supplementary Table S1 , available at Annals of Oncology online.
Results
The clinical history of the three patients is summarized in Table 1 . In late November 2016, she began treatment with palbociclib (125 mg/day orally for 3 weeks followed by 1 week off) with fulvestrant. She continued this treatment until mid-April 2017 when significant hepatic progression was ascertained. The same day, we collected a peripheral blood sample to proceed with ctDNA NGS analysis of a gene panel including coverage of RB1. We identified a substitution in donor splicing site of exon 8 of the RB1 gene [NM_000321.2: c.861þ1G>A; Chr13(GRCh37): g.48937094G>A] ( Figure 1A ) with a 15% allele frequency. This substitution is predicted to affect splicing site and exon 8 deletion inducing a framesift encoding for truncated protein (p.Lys240Serfs*22). Besides the RB1 mutation, we also detected a p.Arg248Trp TP53 mutation [NM_000546.4(TP53): c.742C>T; Chr17(GRCh37): g.7577539G>A] at a 35% allele frequency (sup plementary Figure S1A , available at Annals of Oncology online).
Using the same targeted gene panel, we carried out a tissuebased NGS analysis of a hepatic metastasis biopsy collected 3 months before beginning palbociclib. Analysis detected the p.Arg248trp TP53 mutation, identical to the plasma-based NGS finding, with 51% allele frequency but did not reveal any RB1 mutation despite a good coverage depth (739Â) of RB1 exon 8 splicing site ( Figure 1A ). She received adjuvant chemotherapy (adriamycin, cyclophosphamide, and docetaxel). In January 2009, she began tamoxifen and then switched to exemestane in June 2011. In May 2016, routine blood parameter analysis revealed elevated liver function tests and she was found to have a metastasis in the right hepatic lobe on staging evaluation. Fine needle biopsy of the liver lesion revealed carcinoma consistent with metastatic breast cancer, ER þ (>90%), PR þ (10%-50%) and HER2À. Adjuvant exemestane was stopped and fulvestrant 500 mg was initiated in June 2016 in combination with palbociclib 125 mg on days 1 through 21 of a 28 day cycle.
In June 2016, she started palbociclib (125 mg/day orally for 3 weeks followed by 1 week off) with fulvestrant. No RB1 mutations were detected based on the ctDNA assay (circulating free DNA input ¼ 24.1 ng) that was sent in June 2016, before starting this palbociclib based therapy. Similarly, genomic testing carried out on the tissue-based hepatic metastasis (May 2016) obtained before start of palbociclib did not detect RB1 mutation either.
Following disease progression in February 2017, repeat ctDNA testing (circulating free DNA input ¼ 17 ng) revealed several molecular alterations including a substitution in donor splicing site of exon 22 of RB1 gene [NM_000321.2(RB1): c.2325þ1G>A; Chr13(GRCh37): g.48937094G>A] with a 2.3% allele frequency as well as an exon 19 deletion (V654fs, 0.8% cfDNA; supplemen tary Figure S1B , available at Annals of Oncology online), an exon 3 insertion (I101fs, 0.5% cfDNA), and the E268* mutation (0.4% cfDNA). The c.2325þ1G>A substitution is predicted to affect splicing site inducing an in-frame deletion of exon 22 (p.Thr738_Arg775del). While this mutation has not been described previously in breast cancer, a splice site alteration at exon 22 has been identified in lung cancer and was found to lead to the skipping of exons 22-24 and the loss of a region of Rb involved in the binding of Rb to the E2F-based transcription factor complexes and upregulation of cell cycle genes [11, 12] . The emergence of multiple de novo polyclonal RB1 mutations after treatment with CDK 4/6 inhibitor is outlined in Figure 1B . . She was treated with adjuvant chemotherapy followed by tamoxifen for 3.5 years and then adjuvant exemestane. In January 2015, she was diagnosed with metastatic disease when she presented with cough and dyspnea, and cytologic evaluation of pleural fluid revealed adenocarcinoma consistent with breast cancer.
In January 2015, she began treatment with ribociclib in combination with letrozole in a clinical trial. Her disease responded to this therapy until April 2016 when she progressed with worsening parenchymal pulmonary and hepatic metastases. The liver biopsy from November 2015 obtained while her disease was still responding to ribociclib based therapy revealed no evidence of an RB1 mutation. In March 2016, her disease progressed on the CDK4/6 inhibitor combination therapy and she was subsequently treated with capecitabine followed by nab paclitaxel chemotherapy. In March 2017, ctDNA analysis (circulating free DNA input ¼ 30 ng) revealed a p.His483Tyr RB1 variant in exon 16 [NM_000321.2(RB1): c.1447C>T; Chr13(GRCh37): g.48954326C>T] detected at 10% allelic frequency. This missense variant is predicted to be deleterious by in silico algorithms, and has been described in patients with germline retinoblastoma [13] .
The location of the various RB1 mutations is outlined in Figure 2 .
Discussion
To our knowledge, this is the first report to describe the emergence of acquired resistance to palbociclib or ribociclib with the concurrent development of multiple de novo somatic RB1 mutations in mBC patients. While in this clinical study, it is impossible to state that they are directly involved in the resistance to CDK4/6 inhibitors, nevertheless, the dynamics of their appearance suggest that they possibly emerged under the pressure of CDK 4/6 treatment. The acquired RB1 mutations were detected in three different institutions by three different investigators which adds external validity to the observation.
Primary resistance to palbociclib mediated by loss of the RB1 gene has been demonstrated in pre-clinical models [14] , but acquired resistance to CDK4/6 inhibitors in BC has been less extensively explored. Herrera-Abreu and colleagues investigated mechanisms of 'acquired resistance', and showed that T47D cell line that became resistant to CDK4 inhibitors develop RB1 loss [15] . The investigators then generated a patient-derived tumor xenograft (PDX) utilizing harvested ERþ metastatic tissue that had developed acquired resistance to ribociclib (LEE011). The authors demonstrated the acquisition of a RB1 frameshift mutation (p.Met695fs*26) which was present at a sub-clonal level, and became predominant when the PDX was further exposed to ribociclib.
Analyses of whole-exome sequencing of metastatic lesions obtained from pre-treated but CDK4/6 inhibitor-naïve patients have demonstrated rare RB1 mutations in mBC [16] . However, in our three patients, the somatic RB1 mutations were not present in the metastatic tissue samples or blood samples collected before exposure to palbociclib or ribociclib. Furthermore, in patient #2, no RB1 mutation was detected in pre-treatment ctDNA analysis (or tissue-based analysis) despite pre-treatment cell-free DNA input of 24 ng which is much above the lower limit of detection of the assay (0.1%). Additionally, to address any issue with slight differences in the assay version (V14 in pre-treatment versus V15 in post-treatment), we ran the same assay (V15, in collaboration with the sponsor) and were able to confirm that the four Rb1 alterations seen on the post-treatment sample were not present in the pre-treatment sample. Given the multiple RB1 mutations detected in the post-treatment ctDNA analysis, it is likely that selective pressure from exposure to the CDK 4/6 inhibitor led to these acquired RB1 mutations. An alternate hypothesis would be that the RB1 mutation detected in plasma at progression on CDK inhibition was spatially subclonal and not represented in the metastasis sampled pre CDK inhibition. We detected multiple RB1 alterations, including subclonal alterations, a pattern similar to that observed with the emergence of ESR1 mutations that occur upon selective pressure from aromatase inhibitors in metastatic breast cancer patients [17] [18] [19] [20] , and acquired PTEN alterations in patients treated with PI3K inhibitors [21] . Similar patterns have also been noted in other solids tumors ranging from acquired T790M mutations in patients with lung cancer receiving EGFR inhibitors, to expansion of subclonal KRAS mutations derived from pre-existing clones in primary tumor among patients receiving anti-EGFR treatment for colon cancer [22, 23] .
Finally, understanding the mechanisms of acquired resistance to CDK4/6 inhibitors has significant implications in the clinical setting. As demonstrated by Herrera-Abreu et al. [15] , the 'early adaptation' to CDK4/6 inhibitors was prevented, in cell lines, by combining CDK4/6 and PI3K inhibitors. Similarly, the 'acquired resistance' to palbociclib was prevented by combined inhibition of CDK 4/6 and PI3K in the xenograft model. These results collectively suggest a potential role for combinations of CDK4/6 and PI3K-inhibitors in treatment-naïve breast cancer to maximize tumor response and delay acquired resistance.
In conclusion, we have demonstrated the presence of multiple somatic RB1 mutations in ctDNA samples collected following initial response followed by disease progression on palbociclib or ribociclib in three patients with ERþ HER2À mBC. These findings warrant confirmation in a larger study as well as functional validation. Further research is needed to identify the frequency of these mutations and how these mutations temporally emerge under selective pressure of CDK 4/6 treatment. In addition, failure to find acquired RB1 mutations in mBC patients being treated with novel combinations of CDK4/6 and other pathway inhibitors could represent the starting point for developing strategies targeted to overcome or prevent the unfortunate acquired resistance to CDK 4/6 inhibitor treatments. 
